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Abstract
Background Most terminally ill patients request informa-
tion about their remaining life span. Professionals are not
generally willing to provide prognosis on survival, even
though they are expected to be able to do so from their
clinical experience. This study aims to find out whether the
standardized instruments Palliative Prognostic Index (PPI)
and the Palliative Prognostic Score (PaP-S) are appropriate,
specific, and sensitive to estimate survival time in patients
receiving inpatient palliative care in Germany.
Method PPI and PaP-S were assessed in addition to the
core documentation data set of the Hospice and Palliative
Care Evaluation for patients admitted to the palliative care
units in Aachen, Bonn, and Cologne. Time of survival was
assessed with repeated phone calls to the family and was
defined as the difference between the day of completion of
the instruments (excluded) and the day of death (included).
Results Survival time was compared with physicians’
estimations and prognostic scores in 83 patients. Whereas
the estimates of the PPI and the PaP-S correlate highly,
even higher correlations are found for the physicians’
prognosis and the scores. Correlations between survival
time and the prognostic scores or physicians’ prognosis
were lower. Physicians’ estimations overestimated survival
time on average fourfold. Estimations were more often
correct for very good and very bad prognosis.
Discussion The prognostic scores are not able to produce a
precise reliable prognosis for the individual patient.
Nevertheless, they can be used for ethical decision making
and team discussions. Estimating survival time from
clinical experience seems to be easier for very bad or very
good prognosis for physicians.
Keywords Palliativecare.Prognostication.
Prognosticscores.Terminallyill.Survivaltime.
Physicians’estimation.PalliativePrognosticIndex(PPI).
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Introduction
Prognostication, along with diagnosis and treatment, is one of
the most central issues in palliative care [1] and is a key factor
in decision making for caregivers, patients, and their families
in all medical settings. “One of the key roles for palliative care
services is to initiate discussions on prognosis and goals of
care” [1]. On the other hand, prognostication in palliative care
may be challenged as irrelevant for patients with restricted life
expectancy or even as unethical, as communication of a
definite and limited time frame may burden the patient.
However, indications of specific treatments, choice of medi-
cation,anddecisionsoncareanddischargeplanningareusually
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the estimated survival time. Estimation of survival time and
prognostic uncertainty were named as major factors in
decision making on antibiotic treatment in palliative care [3].
The rationale of the estimations by health care profes-
sionals is rarely defined, even though it forms the basis of
these important decisions. In a study by Fallowfield et al.,
88% of terminally ill patients ask for information about
their remaining life span while less than 8% are willing to
receive only good or no detailed information [4]. The
question “How long do I have?” addresses patients’ needs
and wishes for the residual life span, such as setting up a
proxy for decision making, putting financial and social
affairs in order, or organizing funeral details [5].
Communicating prognostic information may raise ethical
problems and cause tense dilemmas. It is challenging for
physicians to balance between realistic information without
increasing anxiety and reducing trust, on one hand, and
allowing hope and optimism without creating unrealistic
expectations, on the other hand [6].
Professionals are not generally willing to provide prognostic
information and do not feel adequately prepared for this task,
even though they are expected to know from their clinical ex-
perience.Morethanhalffeelpoorlytrainedandreport difficulty
in formulating and communicating prognosis to patients [1].
Some studies on prognostication report mean ratios of
predicted to observed survival time with a factor of 3–5[ 7],
showing overoptimistic estimations of the physicians. Sex,
years of medical practice, board certification, cultural
background, or self-rated optimism have been investigated
as possible bias toward optimism, but no homogenous
results could be found [4, 7].
To improve assessment of prognosis and alleviate
communication with terminally ill patients, several work-
groups have developed prognostic scoring systems on
survival time in palliative care [1, 8]. To our knowledge,
these scores have not been tested in a head-to-head
comparison yet. There is also no information whether the
prognostic scores can be used in German palliative patients.
This study compared the Palliative Prognostic Index (PPI)
and Palliative Prognostic Score (PaP-S) with physicians’
estimation and survival time in palliative care patients in
Germany and investigated how appropriate, specific, and
sensitive the prognostic scores were in this setting.
Materials and methods
Study plan
The two prognostic scores PPI and PaP-S were assessed by
experienced physicians as part of the Hospice and Palliative
Evaluation (HOPE) in 2005 [9, 10]. HOPE is a standard-
ized documentation system with a core documentation form
and a range of modules, among them is the prognostic
module with the two prognostic scores. HOPE is used in a
nationwide survey with a 3-month period of recruitment
each year, as a quality assurance program for inpatient
palliative care units in Germany [11]. Thirty patients
recruited consecutively to each of the palliative care units
in Aachen, Bonn, and Cologne in the evaluation period
from the 15th of June to the 15th of October 2005 were
included in this survey. Additional information was
collected on survival times for these patients. The depart-
ments in Aachen (nine beds) and Bonn (nine beds) are run
by physicians with a subspecialty in palliative medicine and
a specialist degree in anesthesiology; the department in
Cologne (11 beds) is run by a physician with a subspecialty
in palliative medicine and a specialist degree in neurology.
Informed consent was not obtained from the patients, as
the assessment was an additional part of the regular
documentation and quality assurance program of the units.
Therefore, an evaluation of the ethics committee was not
necessary. Nevertheless, an information sheet for the
patients and their families was provided to explain the
background and method of the study. All data were entered
anonymously in an electronic database.
Evaluation of the survival time of patients was essential
for the research project. For patients treated as inpatients
until the time of death, the survival time could be calculated
from the clinical documentation. Patients discharged home
to hospice or nursing home were contacted repeatedly, and
time of death was elicited by phoning families, general
practitioners, nursing home staff, and other relevant carers
until June 2008. Phone calls were included if possible in the
regular follow-up procedure for discharged patients. Sur-
vival time was defined as the difference between the day of
completion of the instruments (excluded) and the day of
death (included).
Prognostic scores
The PaP-S [12] allows identification of a subgroup of
patients with advanced disease and very bad prognosis.
After validating the PaP-S in a multicenter study with
Italian palliative care patients, the rating system was
modified in relation to the empirical results [13]. The
PaP-S contains six items: dyspnea, anorexia, the Karnofsky
performance status, clinician prediction of survival, total
white blood count, and lymphocyte percentage. Although
the clinicians’ prognosis is imprecise, it is included as an
important parameter in the final assessment tool. The sum
score of all items in a range from 0 to 17.5 points is
separated into three categories: category 3 (0–5.5 points)
predicts a probability higher than 70% of at least 30 days
44 Support Care Cancer (2010) 18:43–49survival time, category 2 (5.6–11 points) predicts a
probability between 30% and 70%, and finally, category 1
(11.1–17.5 points) predicts a chance lower than 30% of the
4-week survival time. The PaP-S was validated for Italian
hospice–home care patients in a multicenter study and
successfully used for hospitalized patients with terminal
cancer, advanced cancer, and various end-stage noncancer
illnesses.
The PPI has been constructed in extension of the
Palliative Performance Scale and contains five variables:
the performance status, oral intake, edema, dyspnea at rest,
and delirium [8]. The performance status is a modification
of the Karnofsky index. A performance status score lower
than 50% predicts a chance of survival of 10% for 6 months
[14]. The sum score of the PPI ranges from 0 to 15 points.
Sum scores above six points (category 1) are associated
with a 20% chance of survival for 3 weeks; a sum score
above four points (category 2) is equivalent to a chance of
survival of 20% for 6 weeks. Validated in a Japanese
palliative care inpatient unit, the PPI predicted survival
times with a sensitivity of 91% and a specificity of 67% [8].
For this study, sum scores lower than four points were used
as a third category to test whether the survival time of this
group of patients is significantly longer than in the other
two categories.
The physicians’ estimation of survival time was docu-
mented in the PaP-S, as this instrument includes an item
requiring physicians to estimate survival time on a six-step
categorical scale (1–2, 3–4, 5–6, 7–8, 9–10, 11–12, or more
than 12 weeks).
Sensitivity (right positive/(right positive + false nega-
tive)) and specificity (right negative/(right negative + false
positive)) was calculated for each PPI category as well as
for PaP-S categories 1 and 3 separately.
Thepositivepredictivevalueastheamountofpatientswith
a poor prognosis (category 1) who died within the given
timeframe and the negative predictive value as the amount of
patients with a good prognosis (category 3) who survived the
given timeframe are given for both prognostic instruments.
Empirical analyses were carried out using SPSS for
Windows, version 14.0.
Results
Study population
A total of 90 patients were recruited. Data on 83 patients were
used for analysis; seven data sets were incomplete. The
palliative care unit in Aachen included 30%, Bonn 35%, and
Cologne 35% of the analyzed study population.
Mean patient age was 63 years (standard deviation (SD)
13years,range 37to87years),with53%femaleand47% male
patients. Patientshad ameansurvival time of 50 days(SD = 98,
range 0 to 737 days). Main diagnoses are shown in Table 1.
The PaP-S assigned 19% of all patients to category 1
(poor prognosis), 27% to category 2 (intermediate progno-
sis), and 47% to category 3 (good prognosis); 7% were
missing values. No patient in category 1 (standard less than
30% survivors), 32% in category 2 (standard 30–70%), and
Main diagnosis Number of patients Percentage
Malignant neoplasms
Digestive organs 19 23
Respiratory and intrathoracic organs 16 19
Breast 9 11
Lymphoid, hematopoietic, and related tissue 7 9
Female genital organs 7 9
Ill-defined, secondary, and unspecified sites 4 5
Male genital organs 4 5
Urinary tract 3 4
Skin 3 4
Thyroid and other endocrine glands 2 2
Mesothelial and soft tissue 2 2
Lip, oral cavity, and pharynx 2 2
Eye, brain, and other parts of central nervous system 1 1
Others
Diseases of the circulatory system 2 2
Diseases of the respiratory system 2 2
Total 83 100
Table 1 First diagnosis (ICD)
of the study population
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30 days.
The PPI assigned 29% of all patients to category 1 (poor
prognosis), 19% to category 2 (intermediate prognosis), and
46%tocategory3(goodprognosis);6%weremissingvalues.
Eight percent of the patients in category 1 survived for more
than 3 weeks (standard 20%), 12% of those in category 2
(standard 20%), and 50% in category 3 (standard >20%)
survived for more than 6 weeks. Data on sensitivity/positive
rate and specificity/negative rate can be seen in Table 2.
The positive predictive value as the amount of patients
with a poor prognosis (category 1) who died within the
given timeframe of (a) 30 days of the PaP-S reaches 100%
(16 out of 16) and (b) 3 weeks of the PPI reaches 92% (22
out of 24). The negative predictive value as the amount of
patients with a good prognosis (category 3) who survived
the given timeframe of (a) 30 days of the PaP-S reaches
54% (21 out of 39) and (b) 6 weeks of the PPI reaches 50%
(19 out of 38).
The survival functions (Kaplan–Meier) as the decreasing
cumulative survival of patients in dependence on lifetime is
pictured separately for the scoring categories 1: bad, 2:
moderate, and 3: good prognosis of (a) the PaP-S and (b)
the PPI in Fig. 1a, b. Chi-square for the distribution of
survival (Mantel–Cox) for the curves of the different score
categories was highly significant (p<0.01) for both prog-
nostic instruments.
The prognosis scores PaP-S and PPI correlated highly
(r(PaP-S; PPI)=0.704), as well as physicians’ estimation with
the instruments scores: r(PPI; physician)=0.726 and r(PaP-S;
physician)=0.857. However, only moderate correlations were
found between survival time and both scores as well as
between survival time and physicians’ estimation. For data
on single correlations, please see Table 3. Number of data
sets is varying because missing values in single items of
one prognostic instrument prevent from calculating sum
scores and the analysis of their correlations.
Physicians’ estimation of survival time
Comparing the six categories of the PaP-S variable on the
physician’s prediction of survival with survival times 31%
of the physicians’ ratings were in the correct category, 5%
were overpessimistic, and 63% were too optimistic; 1%
were missing values. Physicians overestimated survival
times with a mean factor of 4.2 (SD = 6.5; range 0.3–43).
Overestimation was subject to a centre effect, as the mean
factor was 5.2 in Aachen (52% overoptimistic and 36%
Category Sensitivity Specificity
PaP-S 1 (<30% chance for 30 days survival) 67% 100%
2 (30–70% chance for 30 days survival) ––
3 (>70% chance for 30 days survival) 78% 65%
PPI 1 (20% chance for 3-week survival) 51% 94%
2 (20% chance for 6-week survival) 46% 84%
3 (>20% chance for 6-week survival) 83% 66%
Table 2 Sensitivity and
specificity of PaP-S and PPI
categories 1, 2, and 3
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Fig. 1 a Survival function as the decreasing cumulative survival of
patients in dependence on time (days) separately for the scoring
categories 1: bad, 2: moderate, and 3: good prognosis of the PaP-S. b
Survival function as the decreasing cumulative survival of patients in
dependence on time (days) separately for the scoring categories 1:
bad, 2: moderate, and 3: good prognosis of the PPI
46 Support Care Cancer (2010) 18:43–49accurate hits), 3.7 in Bonn (62% overoptimistic und 35%
accurate hits), and 3.9 in Cologne (72% overoptimistic and
24% accurate hits). Accurate hits were more frequent in
categories 1 and 3 of the PaP-S (46% accurate hits each)
than in category 2 (8% accurate hits). A similar distribution
was found for the PPI with 56% accurate hits in category 1,
0% in category 2, and 44% in category 3.
Discussion
Discussion of survival time is one of to the most sensitive
and ethically challenging issues in palliative care. Patients
may be torn between anxiety and fear on one side and hope
for survival or a chance to manage their remaining life span
despite the worst prognosis on the other side.
Relatives and carers may need accurate information on
prognosis, as important decisions may depend on it. As an
example from our experience, the son of a patient was
asking for the expected time of survival, as he wanted to
use his accumulated holiday leave for the time his father
died, and was afraid that if he took his leave too soon, he
would have to work at the time of his father’s death. Other
examples include a visiting relative from Canada asking
whether she should reschedule her return flight in 3 weeks
time, or a patient asking whether he should cancel the
holiday trip planned in 2 months.
Information on prognosis influences the patients’ own
conceptions of their future and the ideas on maintaining
quality of life for the remaining lifetime as well as their
choices in medical technologies and treatments. Patients
prefer an “individualized and realistic disclosure from a
confident and supportive cancer specialist” [6] which is
understood as hope giving. Physicians, on the other hand,
are reluctant to communicate prognosis unless asked and
try to be unspecific, but optimistic [5]. These ideas are
slightly contradictory. Additionally, there is a discrepancy
between the formulated prognosis (as discussed in the
team) and what is communicated to patient and family.
However, there can be no doubt that it is the patient’s right
to make plans for the residual life span. In consequence, he
can also expect a prognosis as precise as possible.
Currently, the estimation of survival at the palliative care
units participating in this study depends mostly on “gut
feeling” as results of clinical observation and experience of
the teams. Patients and their families get information about
the prognosis as far as they want to know. However, as
shown by the results of this study, estimations of survival
times often were incorrect, and most were often too
optimistic. This confirms other trials showing overoptimis-
tic prognosis by clinicians. Christakis et al. reported that
only 20% of predictions were accurate and 63% overopti-
mistic by a factor of 5.3 in the physicians’ estimation of
survival time [7]. Similar results are found by Gripp et al.
who found 71–96% of estimates of survival on patients
who died within 1 month to be overoptimistic [15].
Christakis et al. observed the effect that a stronger
physician–patient relationship is associated with lower
prognostic accuracy and that more experienced physicians
were more accurate. Considering the conflict between
experience and relationship, a trend toward second opinion
among colleagues seems meaningful as a more neutral
source of opinion without personal investigation into the
outcome for the patient [7].
Prognostic scores would offer additional accuracy for
prognostication and thus could facilitate ethical decision
making and communication with patient and family.
However, even if prognosis scores provide meaningful
results for groups of patients with satisfactory specificity
and sensitivity, results should be considered carefully for
the individual patient, as considerable variation from
default is possible.
To our knowledge, available prognostic scores have not
been tested in a head-to-head comparison yet. Results from
this study show no advantage between PaP-S and PPI. As
the PaP-S and the PPI correlate highly in their prognosti-
cation, any one of them should be adequate for clinical use
in addition to the physicians’ estimation. As both only have
a moderate correlation with survival time, clinicians should
not rely only on them as the only or main instrument of
prognosis. The PPI correlated better with survival time than
the PaP-S; however, sensitivity for bad and moderate
prognosis was lower than for the PPI.
Physicians’ estimation of survival time reached the
lowest correlation with the actual survival. This may be
due to the form of this specific question, which was
included as an item in the PaP-S. Physicians had to estimate
life time in two weekly steps, which seemed to be difficult.
Table 3 Spearman rank correlations of prognostic scores PaP-S and PPI, survival of palliative patients, and physicians’ estimate of survival
PaP-S PPI Survival of palliative patients Physicians estimate of survival (PaP-S)
PaP-S 0.704* (N=72) −0.575* (N=77) 0.857* (N=77)
PPI 0.704* (N=72) −0.678* (N=78) 0.726* (N=74)
Survival of palliative patients −0.575* (N=77) −0.678* (N=78) −0.556* (N=79)
*p<0.01
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with both prognostic instruments. This leads to the
conclusion that this single item may replace the test.
However, the degree of overestimation in the single item
and the low correlation with survival time call for
additional input for prognostication.
Detailed analysis showed that clinicians were able to
score poor or good prognosis more accurately than
intermediate prognosis. In line with this finding, the PPI
and the PaP-S were as well suited to predict which patients
had the poorest survival, but they were less adequate to
distinguish between good and intermediate prognosis. This
points toward a huge uncertainty with intermediate prog-
nosis. Prognostic assessment tools seem to be most needed
for intermediate prognosis. However, in our study, both
instruments were not suited for intermediate prognosis.
Regarding the limitations of scoring systems, Henderson
et al. tried to establish a best statistical model for prediction
which surprisingly included the clinicians’ prediction as an
additional risk factor as well, although not accurate [16].
However, the inclusion of the physicians’ estimate of
survival as on the items of the PaP-S seems to produce a
dilemma. A prognostic index would be most useful for
those occasions where the physician is uncertain of the
patient’s survival and relying on a score which give large
weighting to the clinicians estimate may be a major
drawback [5]. Following the results of our study, scoring
systems on prognosis of survival time seem to be least
useful for those patients [5] with neither a good nor a poor
prognosis because here both physicians’ estimates as well
as the existing prognostic instruments lack precision.
Physicians’ estimations may have been biased by the
format of the item, requiring them to differentiate steps of
2 weeks survival time which demands a very specific
estimate. Using broader categories might have resulted in
less overestimation. However, clinical practice frequently
requires prognostication with this accuracy, for example, if
family leave, travel, or holiday schedules or care plans have
to be realized.
Limitations of this study are a rather small sample size,
and correlations may have been masked by outliers in the
restricted sample. However, methodological considerations
restricted the number of participating centers and the
sample size should have been large enough to demonstrate
the usefulness of the scores in clinical practice.
The parallel consideration of the physicians’ estimate as
an item of one of the scores (PaP-S), on one hand, and as a
comparator for clinical prognostication, on the other hand,
may have confounded the evaluation. Using another scale
for the physicians’ estimate of survival and not the small-
step scoring system of the PaP-S item on the physicians’
estimate could have given more insight into the derivation
and determination of their clinical prognostication.
Our results demonstrate the need for more robust and
better fitting prognostic tools that can be used in clinical
palliative care practice to supplement the clinical estimation
of survival. Whereas poor scores in both prognostic scales
adequately identified patients with poor prognosis, patients
with good scores often did not have longer survival times.
Both scores are constructed to differentiate prognostic
chances for several weeks. In clinical practice, it would be
valuable to have a set of different scores with different time
frames. More specifically, a sensitive prognostic score with
a shorter time frame, allowing identification of patients in
the final days of life, would be helpful for decision making
in the terminal phase.
Prognostication with adequate sensitivity and specificity
is only the first step in the care of patients with short life
expectancy. Not only using prognosis carefully in ethical
decision making but also communication strategies with
patients and families on prognosis and on the best course of
therapy have to supplement prognostication.
Using the available prognostic scores in clinical practice,
with due consideration of the shortcomings, will train
clinicians in these skills and will facilitate discussion and
communication on prognosis.
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